Search
BioLine RX Ltd
BLRXAdd to Watchlist
3.285USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.29MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+3.79%
1 Month
-2.23%
6 Months
+17.32%
Year to Date
+18.59%
1 Year
-26.84%
Key Figures
3.220Open
3.285High
5.06KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.12%Turnover Ratio
3.170Prev. Close
3.167Low
12.30KTurnover
LossP/E Static
0.73P/B
0.00%Div Yield TTM
-5.08%ROA
7.77052wk High
0.98Volume Ratio
-9.22MNet Profit
4.35MShares
-0.4920EPS TTM
1.49Beta
-12.80%ROE
2.15052wk Low
3.72%Amplitude
79.38%Gross Margin
14.29MMarket Cap
-1.49Reward/Risk
3.78%Risk Rate
TradingKey Stock Score of BioLine RX Ltd
Currency: USD Updated: 2026-07-02Key Insights
BioLine RX Ltd's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 189 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to trend up.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioLine RX Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
BioLine RX Ltd Highlights
StrengthsRisks
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.18M.
Fairly Valued
The company’s latest PE is -6.68, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.33K shares, decreasing 69.29% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
17.500
Target Price
+452.05%
Upside Space
BioLine RX Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioLine RX Ltd Info
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Ticker SymbolBLRX
CompanyBioLine RX Ltd
CEOSerlin (Philip Adam)
Websitehttps://www.biolinerx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of BioLine RX Ltd (BLRX)?
The current price of BioLine RX Ltd (BLRX) is 3.29.
What is the symbol of BioLine RX Ltd?
The ticker symbol of BioLine RX Ltd is BLRX.
What is the 52-week high of BioLine RX Ltd?
The 52-week high of BioLine RX Ltd is 7.77.
What is the 52-week low of BioLine RX Ltd?
The 52-week low of BioLine RX Ltd is 2.15.
What is the market capitalization of BioLine RX Ltd?
The market capitalization of BioLine RX Ltd is 14.29M.
Is BioLine RX Ltd (BLRX) currently rated as Buy, Hold, or Sell?
According to analysts, BioLine RX Ltd (BLRX) has an overall rating of Buy, with a price target of 17.50.
What is the Earnings Per Share (EPS TTM) of BioLine RX Ltd (BLRX)?
The Earnings Per Share (EPS TTM) of BioLine RX Ltd (BLRX) is -0.49.